Skip to main content
RYVU Therapeutics S.A. logo

RYVU Therapeutics S.A. — Investor Relations & Filings

Ticker · RVU ISIN · PLSELVT00013 LEI · 2594003WO9Q9HHAFL031 WAR Professional, scientific and technical activities
Open in API
Filings indexed 803 across all filing types
Latest filing 2025-09-18 Audit Report / Informat…
Country PL Poland
Listing WAR RVU

About RYVU Therapeutics S.A.

https://ryvu.com/

Ryvu Therapeutics is a clinical-stage drug discovery and development company specializing in novel small molecule therapies for oncology. The company's research focuses on emerging biological targets and pathways, including kinase inhibition, synthetic lethality, and immuno-oncology, to develop precise cancer treatments. Its pipeline features several candidates in various stages of development. Key clinical-stage assets include Romaciclib (RVU120), a selective CDK8/19 kinase inhibitor for treating hematologic malignancies like acute myeloid leukemia (AML) and myelofibrosis, and Dapolsertib (MEN1703), a PIM/FLT3 inhibitor. The company also advances preclinical programs, such as an MTA-cooperative PRMT5 inhibitor for solid tumors with MTAP deletion.

Recent filings

Filing Released Lang Actions
Raport biegłego z przeglądu śródrocznego sprawozdania finansowego Ryvu Therapeutics S.A. H1 2025 ENG
Audit Report / Information Classification · 1% confidence The document is an 'Independent Auditor's Report on Review of Interim Condensed Financial Statements'. It is a standalone audit report specifically addressing the review of interim financial statements, rather than the financial statements themselves or an annual report. According to the filing definitions, standalone audit reports and results of regulatory reviews fall under the 'AR' (Audit Report / Information) category. H1 2025
2025-09-18 English
Raport biegłego z przeglądu śródrocznego sprawozdania finansowego Ryvu Therapeutics S.A. H1 2025 PL
Audit Report / Information Classification · 1% confidence The document is a 'Report of the Independent Auditor' (Raport niezależnego biegłego rewidenta) regarding a review of interim condensed financial statements. It is not the financial report itself, but rather the audit/review opinion issued by Ernst & Young for Ryvu Therapeutics S.A. Based on the definitions provided, standalone audit reports and review results fall under the 'AR' (Audit Report / Information) category. H1 2025
2025-09-18 Polish
Sprawozdanie Finansowe Ryvu Therapeutics S.A. H1 2025 ENG
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Interim Financial Statements' for Ryvu Therapeutics S.A. covering the period from 1 January 2025 to 30 June 2025. It includes comprehensive financial statements (Statement of Comprehensive Income, Statement of Financial Position, etc.) and detailed notes to the financial statements. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. H1 2025
2025-09-18 English
Sprawozdanie Zarządu Ryvu Therapeutics S.A. z działalności H1 2025 ENG
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RYVU THERAPEUTICS S.A. H1 2025 Report' and contains detailed financial statements, including a statement of financial position and a statement of comprehensive income for the period ending June 30, 2025. It includes management board comments, asset/liability structures, and pipeline information. As it covers a period shorter than a full fiscal year (H1/interim) and contains substantive financial data, it is classified as an Interim/Quarterly Report. H1 2025
2025-09-18 English
Sprawozdanie Finansowe Ryvu Therapeutics S.A. H1 2025 PL xades
Regulatory Filings
2025-09-18 Polish
Sprawozdanie Finansowe Ryvu Therapeutics S.A. H1 2025 PL xhtml
Regulatory Filings
2025-09-18 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.